Company profile
Zhimeng Biopharma
Privately held: no public share price (Shanghai small-molecule biopharma (chronic hepatitis B, epilepsy, pain, stroke), founded 2017. Series A/B VC-funded (~$49-103M raised depending on source); no evidence found of a STAR Market or other IPO as of research date. Privately held. Sources: https://clinicaltrials.gov/study/NCT06612775 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://tracxn.com/d/companies/zhimeng-biopharma/__S3dDM8vkjKXrWG4l7hHBVLUT4jdqBa8MYfBXGAgeRPE ; http://core-biopharma.com/ Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | KCNQ2/3 (Kv7.2/7.3) potassium channel (opener)Small molecule | Epilepsy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.